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Background: Hallmarks of CNS inflammation, including microglial and astrocyte activation, are prominent features
in post-mortem tissue from amyotrophic lateral sclerosis (ALS) patients and in mice overexpressing mutant superoxide
dismutase-1 (SOD1G93A). Administration of non-targeted glucocorticoids does not significantly alter disease progression,
but this may reflect poor CNS delivery. Here, we sought to discover whether CNS-targeted, liposomal encapsulated
glucocorticoid would inhibit the CNS inflammatory response and reduce motor neuron loss. SOD1G93A mice were
treated with saline, free methylprednisolone (MP, 10 mg/kg/week) or glutathione PEGylated liposomal MP (2B3-201,
10 mg/kg/week) and compared to saline treated wild-type animals. Animals were treated weekly with intravenous
injections for 9 weeks from 60 days of age. Weights and motor performance were monitored during this period.
At the end of the experimental period (116 days) mice were imaged using T2-weighted MRI for brainstem pathology;
brain and spinal cord tissue were then collected for histological analysis.
Results: All SOD1G93A groups showed a significant decrease in motor performance, compared to baseline,
from ~100 days. SOD1G93A animals showed a significant increase in signal intensity on T2 weighted MR images, which
may reflect the combination of neuronal vacuolation and glial activation in these motor nuclei. Treatment with 2B3-201,
but not free MP, significantly reduced T2 hyperintensity observed in SOD1
G93A mice. Compared to saline-treated and
free-MP-treated SOD1G93A mice, those animals given 2B3-201 displayed significantly improved histopathological
outcomes in brainstem motor nuclei, which included reduced gliosis and neuronal loss.
Conclusions: In contrast to previous reports that employed free steroid preparations, CNS-targeted anti-inflammatory
agent 2B3-201 (liposomal methylprednisolone) has therapeutic potential, reducing brainstem pathology in the SOD1G93A
mouse model of ALS. 2B3-201 reduced neuronal loss and vacuolation in brainstem nuclei, and reduced activation
preferentially in astrocytes compared with microglia. These data also suggest that other previously ineffective therapies
could be of therapeutic value if delivered specifically to the CNS.
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Amyotrophic lateral sclerosis (ALS) is the most preva-
lent type of motor neuron disease [1]; the SOD1G93A
mouse [2] closely models the progressive motor neuron
pathology of human ALS and has been useful for the
study of mechanisms of selective motor neuron death.
Neuronal degeneration and tissue vacuolation is accom-
panied by changes in magnetic resonance imaging (MRI)
parameters [3,4] leading to the possibility of using MRI* Correspondence: daniel.anthony@pharm.ox.ac.uk
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unless otherwise stated.as an in vivo biomarker of pathology in addition to con-
ventional behavioural and histological endpoints. In par-
ticular we have shown previously that T2 MRI is a sensitive
pathological biomarker in SOD1G93A mice [5].
The SOD1G93A mouse displays astrocyte and microglial
activation, which are established hallmarks of a CNS
inflammatory response [6], and are well-recognised in
individuals with ALS [7-9]. Astrocytes and microglia be-
come activated pre-symptomatically, and this becomes
more widespread and evident as the disease progresses
[10,11]. The inflammatory response in ALS, which cor-
relates with disease progression [12], has provoked the
trial of a number of anti-inflammatory agents as potentialtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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therapeutic approaches have translated to the clinic. In par-
ticular, despite preclinical studies which suggest that ste-
roids might be of value in the treatment of ALS [17], a
study investigating the therapeutic potential of prednisol-
one and azathioprine in a mixed population of motor
neuron disease patients, including ALS patients, found
only limited differences between treatment groups [18].
It therefore remains contentious whether corticosteroids
could afford some therapeutic benefit in ALS. Improved
delivery of anti-inflammatory agents to the CNS may allow
more definitive assessment of the therapeutic potential of
these drugs in ALS.
The blood–brain barrier (BBB) regulates the entrance
of many lipophilic substances, including steroids into
the CNS. Studies indicate that BBB penetrance for meth-
ylprednisolone is lower than expected, due to efflux
from the CNS by p-glycoprotein [19]. Therefore, in-
creasing the sustained delivery of steroid compounds
into the CNS may be a way to maximize the therapeutic
effect, while reducing side effects from the increased
blood concentrations required to achieve adequate CNS
delivery. Glutathione PEGylated liposomal methylpred-
nisolone (2B3-201) overcomes these problems by chan-
ging the pharmacokinetics and the biodistribution of the
drug and, most importantly, targeting endogenous gluta-
thione transporters at the BBB [20]. This drug delivery
system has been used successfully in a murine model of
multiple sclerosis [21], where it was found that 2B3-201
reduced clinical severity significantly more than either
non-targeted liposomes or unpackaged methylpredniso-
lone, and empty targeted liposomes had no effect on the
disease severity. Therefore this effect can be attributed
to the sustained enhanced delivery of methylpredniso-
lone into the CNS. Thus we sought to discover whether
2B3-201 would be more effective than free steroid at im-
proving the MRI, behavioural and histological endpoints
in the SOD1G93A model of ALS.
Results
Behaviour and weights
The mean weight of all groups of mice increased over
time, and no significant difference between any of the
groups was noted at any time point (Figure 1 – A, B)
(ANOVA p>0.05). Owing to the variation in weights
at baseline between the groups (Figure 1A), we per-
formed the analysis after accounting for baseline weight
(Figure 1B). However, there was still no significant differ-
ence between groups after this normalization (ANOVA
p>0.05). We confirmed this for the whole time course using
area under the curve (AUC) analysis (Figure 1 – D, left)
(p>0.05).
For the rotarod test, a significant effect of time-point was
found (p < 0.001) together with a significant interactionbetween time and treatment (p < 0.01). WT mice remained
on the apparatus for longer than all of the SOD1G93A
groups at all time points (Figure 1 – C) (p < 0.05). A
decline in motor performance was evident as the dis-
ease progressed in all SOD1G93A mice, and reached
significance from baseline (p < 0.05) between 80 and
95 days (SOD1G93A saline, 95 days; SOD1G93A free MP,
81 days; SOD1G93A 2B3-201, 88 days). No difference was
found between SOD1G93A treatment groups at any time
point (p > 0.05). AUC analysis (Figure 1 – D, right) also
showed a significant difference between groups (ANOVA
p < 0.001). Post-hoc comparisons revealed a significant
difference between WT and all SOD1G93A treatment
groups (p < 0.001). In SOD1G93A mice treated with 2B3-
201, a significantly greater AUC was found compared
with SOD1G93A mice treated with free MP (p<0.05), but
no significant difference was seen between any of the
other SOD1G93A treatment comparisons (p>0.05).
T2 MRI and tissue vacuolation
To discover whether 2B3-201 treatment had any effect
on brainstem pathology in vivo, mice were scanned with
T2 MRI. SOD1
G93A mice treated with saline had increased
T2 signal intensity in the facial nucleus compared to sur-
rounding grey matter (median 37.3 [interquartile range
9.2]%) (Figure 2 – B, E, H, K, N), which was significantly
greater than T2 intensity in WT mice (p < 0.001), where
no such signal change was seen. SOD1G93A mice treated
with free MP showed a similar increase in signal intensity
(32.5 [3.9]%), which was not significantly different from
SOD1G93A treated with saline (p > 0.05). However, the sig-
nal increase in SOD1G93A mice treated with 2B3-201 was
attenuated (24.8 [5.8]%), and was significantly lower than
both SOD1G93A mice treated with saline and mice treated
with free MP (p < 0.01). The same pattern was present in
both the trigeminal (Figure 2 – A, D, G, J, M) and hypo-
glossal nuclei (Figure 2 – C, F, I, L, O), with attenuation in
signal intensity for SOD1G93A mice treated with 2B3-201
compared with saline and free MP.
Histological confirmation of vacuolation
Brainstem sections were stained with haematoxylin and
eosin as described in the methods, and vacuolation was
quantified in the three nuclei. For WT mice treated with
saline, the neuropil was normal in all cases, with no vac-
uoles present. In the facial nucleus (Figure 3 – E-H, R),
a significant difference in the amount of vacuolation was
evident between the treatment groups (Kruskal-Wallis
p < 0.001). Substantial vacuolation was found in SOD1G93A
mice treated with both saline (0.179 [0.033] mm2) and free
MP (0.168 [0.054] mm2), which were not significantly
different from one another (p > 0.05). In contrast, vacuol-
ation in SOD1G93A mice treated with 2B3-201 (0.143
[0.041] mm2) was significantly lower than SOD1G93A mice
Figure 1 Disease progression assessed by weight and motor behaviour. Weight data (unadjusted – A; normalized at 60 days – B) shows a
gradual increase in weight in all groups, with no significant difference between genotypes or treatment groups at any time point. Rotarod scores
(C) were higher at all time points for WT compared with all SOD1G93A treatment groups, and all SOD1G93A groups showed a typical decline over
time, with no significant difference between any of the treatment groups. There was no significant difference between groups for weight data
with area-under-the-curve analysis (D); SOD1G93A 2B3-201 had significantly greater area under the curve (increased motor scores) compared with
free MP, but there was no difference when compared with SOD1G93A saline. Data are presented as mean ± standard error. *** p<0.001.
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in the trigeminal (Figure 3 – A-D, Q) and hypoglossal nu-
clei (Figure 3 – I-L, S). However, in the trigeminal nucleus,
in addition to being significantly lower than SOD1G93A sa-
line, vacuolation was significantly lower in SOD1G93A mice
treated with 2B3-201 compared with mice treated with free
MP (p<0.05).Motor neuron counts
Motor neurons were counted using stereological tech-
niques in the three motor nuclei to give the total num-
ber of motor neurons. The number of morphologically
normal motor neurons (i.e. vacuole-free) was also counted
to calculate the percentage of morphologically normal neu-
rons. The number of neurons differed significantly between
Figure 2 Changes in T2 MR signal intensity in cranial motor nuclei following steroid treatment. An increase in signal is present in the
trigeminal (V), facial (VII) and hypoglossal (XII) nuclei in SOD1G93A saline mice (D-F) compared to WT animals (A-C). A comparable signal increase
in seen for SOD1G93A mice treated with free MP (G-I), but in comparison to saline and free MP treated SOD1G93A mice, those treated with 2B3-201
(J-L) show a markedly reduced signal intensity in these three motor nuclei. These data are presented graphically for the trigeminal, facial and
hypoglossal nuclei in M-O respectively. * p < 0.05; ** p<0.01; *** p<0.001.
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cial nucleus (Figure 4 – C-D), WT mice had 2,720
[395] neurons in total, with 92.9 [3.6]% morphologically
normal neurons. The total number of neurons was
lower in all SOD1G93A groups compared with WT mice:
SOD1G93A saline had 1,553 [317] neurons (p < 0.001),
SOD1G93A free MP 1,681 [294] neurons (p < 0.001), and
SOD1G93A 2B3-201 2,039 [277] neurons (p < 0.01), with
more neurons in the SOD1G93A 2B3-201 group than ei-
ther the SOD1G93A saline or free MP group (p < 0.01).
Assessing number of healthy neurons as a percentage of
the total number gives a more subtle assessment of disease
status in the SOD1G93A animals and drug treatment
groups, and this measure also differed significantly between
the treatment groups (Kruskal-Wallis p < 0.001). The per-
centage of morphologically normal neurons was much
lower in all three SOD1G93A groups compared with WT sa-
line controls: 33.0 [12.7]% of neurons were morphologically
normal in the SOD1G93A saline group (p < 0.001), 42.3
[9.8]% in the SOD1G93A free MP group (p < 0.001) and 67.9
[18.9]% in SOD1G93A 2B3-201 mice (p < 0.01). SOD1G93A
2B3-201 mice showed a significantly higher proportion of
morphologically normal appearing neurons compared with
SOD1G93A saline (p < 0.001) and SOD1G93A free MP mice
(p<0.01). The same pattern was seen in the trigeminal
(Figure 4 – A-B) and hypoglossal nuclei (Figure 4 – E-F).
Within a 760 μm block of the ventral horn of the
spinal cord (Figure 4 – G-H), WT mice had a total of1,856 [342] neurons, with 93.5 [4.2]% morphologic-
ally normal neurons. A significant difference in the
number of neurons was found between treatment groups
(Kruskal-Wallis p < 0.001). All SOD1G93A treatment groups
had fewer total neurons compared with WT control
mice: 1,083 [469] neurons in the SOD1G93A saline
group (p < 0.001), 1,032 [282] in the SOD1G93A free MP
group (p < 0.001), and 1,229 [200] in the SOD1G93A
2B3-201 group (p < 0.01). A significant difference was
also evident between treatment groups in terms of mor-
phologically healthy neurons (Kruskal-Wallis p < 0.001).
A smaller percentage of morphologically normal neurons
was observed in the three SOD1G93A treatment groups
compared with WT mice: 60.8 [15.5]% in SOD1G93A
saline mice (p < 0.001), 60.9 [15.2]% in SOD1G93A free
MP mice (p < 0.001), and 67.0 [11.1]% in SOD1G93A 2B3-
201 mice (p < 0.01). However, unlike the three cranial
motor nuclei above, no difference was found between
any of the SOD1G93A treatment groups, either for total
neurons, or percentage morphologically normal neurons
(p>0.05).
Glial cell contribution
Glial cells are know to contribute to neuronal pathology
in both humans, and animal models of ALS [10,11], so
we postulated that 2B3-201 treatment exerted its effects
by altering the inflammatory environment of the CNS,
through astrocytes or microglia.
Figure 3 Mutant SOD1-induced vacuolation is ameliorated by steroid treatment. WT tissue shows staining of large motor neurons (black
arrows) in the cranial motor nuclei (A, E, I) and spinal cord (M), with no structural abnormalities. In contrast, SOD1G93A saline (B, F, J, N) and
SOD1G93A free MP (C, G, K, O) show a reduction in large motor neurons, with more morphologically abnormal neurons (white arrows). There is
also substantial vacuolation. SOD1G93A mice treated with 2B3-201 (D, H, L, P) have reduced vacuolation in the cranial motor nuclei (Q-S). Scale
bar applies to all images. Images shown are representative median values in the graphs. * p<0.05; ** p<0.01; *** p<0.001.
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were stained using an antibody against Iba1 for activated
microglia, and the intensity of stain was quantified as
described in the methods. Iba1 is expressed in all micro-
glia, irrespective of activation state. However, staining
intensity significantly upregulated on activation in re-
sponse to injury or cell death. We processed the tissue
such that low levels of basal expression in WT animals
were below the detection threshold of this technique
(as demonstrated by the very low staining intensity in
WT tissue). Thus the microglia that were counted with
our staining method were mostly of the “activated” variety.
The numbers of Iba1-positive microglia were counted in
the grey matter of the cranial motor nuclei and ventral
horn of the spinal cord.
In the facial nucleus (Figure 5 – E-H, S, T), WT Iba1
staining intensity was 1.8 [0.1] units, and on average
10.6 [3.4] Iba1-positive microglia were evident per
ROI. A significant difference in Iba1 staining intensity
was found between the treatment groups (Kruskal-
Wallis p < 0.001). Iba1 staining intensity was greaterfor all SOD1G93A mice compared with WT, with an average
of 12 units (p < 0.001) and significantly more Iba1-positive
microglia, with an average of 41 microglia per ROI, were
seen in the three SOD1G93A groups compared with WT
mice (p < 0.001). However, there were no differences in
Iba1 staining intensity or number of microglia between
SOD1G93A treatment groups (p > 0.05). The same pattern
was seen in the trigeminal nucleus (Figure 5 – A-D, Q, R),
the hypoglossal nucleus (Figure 5 – I-L, U, V) and the ven-
tral horn of the spinal cord (Figure 5 – M-P, W, X).
Serial brainstem and spinal cord sections were stained
using an antibody against GFAP to reveal astrocytes,
and the intensity of stain was quantified as described
for Iba1 above. It is important to note that GFAP is
only expressed in a subset of astrocytes, and its ex-
pression is increased by inflammatory signaling. Unlike
the white matter, where there is a large population of
GFAP-positive astrocytes, few are typically seen in the
grey matter of WT mice (as demonstrated by the low
staining intensity in WT tissue). The number of GFAP
positive astrocytes was counted in the grey matter of
Figure 4 (See legend on next page.)
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Figure 4 Mutant SOD1-induced motor neuron loss is ameliorated by steroid treatment in cranial motor nuclei but not the lumbar
spinal cord. The total number of neurons (A, C, E, G), and the percentage of morphologically normal neurons (B, D, F, H) are reduced in all
SOD1G93A groups compared with WT mice. The SOD1G93A 2B3-201 treatment group showed a general improvement in total number of neurons
and the proportion of those with a normal morphological appearance, compared with both saline and free MP in the brainstem nuclei. No
improvement was seen in the spinal cord. Frames I and J show an example of a neuron defined as morphologically normal (healthy, I) and
an abnormal neuron with significant vacuolation (J). * p<0.01; ** p<0.001.
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In the facial nucleus (Figure 6 – E-H, S, T), WT saline
GFAP staining intensity was 1.5 [0.9] units, consisting of
2.6 [2.6] GFAP-positive astrocytes per ROI. A significant
difference in the GFAP staining intensity was found
between treatment groups (Kruskal-Wallis p < 0.001).
The GFAP staining intensity was much higher in all
SOD1G93A treatment groups compared with WT mice
(p < 0.001). In addition GFAP signal intensity was signifi-
cantly lower in SOD1G93A 2B3-201 (10.0 [2.3]) compared
with both SOD1G93A saline (17.0 [2.4]) (p < 0.01) and
SOD1G93A free MP (17.3 [5.7]) (p < 0.01). The number
of reactive astrocytes was also significantly different
between groups in the facial nucleus (Kruskal-Wallis
p < 0.001). The number of GFAP+ astrocytes was greaterFigure 5 Iba1 positive microglia are not altered following steroid trea
nuclei (A, E, I), and in the spinal cord (M). SOD1G93A mice treated with salin
much stronger staining for Iba1, both in the three brainstem nuclei and th
SOD1G93A treatment groups. Panels Q, S, U and W show quantification of Ib
and panels R, T, V and X show the density of Iba1+ microglia in these sam
groups compared with WT mice, but no group differences among treatmein the three SOD1G93A treatment groups compared with
WT mice (p < 0.001). SOD1G93A 2B3-201 mice (58.1 [25.3])
had fewer astrocytes compared with both SOD1G93A saline
(111 [28.6]) (p < 0.001) and SOD1G93A free MP mice (105.6
[17.3]) (p < 0.001). The same pattern was seen between the
treatment groups in the trigeminal (Figure 6 – A-D, Q, R)
and hypoglossal nuclei (Figure 6 – I-L, U, V). In the ventral
horn of the spinal cord (Figure 6 – M-P, W, X), WT GFAP
staining intensity was 1.1 [1.3] units, and 3.1 [4.8] reactive
astrocytes were detected per ROI. A significant difference
in GFAP staining intensity and the number of GFAP+
astrocytes overall was also evident between the groups
(Kruskal-Wallis p < 0.001): significantly higher GFAP im-
munoreactivity was seen in all three SOD1G93A groups
compared with WT (p < 0.001), an average of 15 units
or 38 cells/ROI between the three SOD1G93A treatmenttment. WT Iba1 immunoreactivity was very low in the cranial motor
e (B, F, J, N), free MP (C, G, K, O) and 2B3-201 (D, H, L, P) showed
e spinal cord. No difference was found in immunoreactivity between
a1 staining intensity in the brainstem motor nuclei and spinal cord,
e regions, showing increased expression in all SOD1G93A treatment
nts. Scale bar applies to all images. * p<0.05; ** p<0.01; *** p<0.001.
Figure 6 GFAP positive astrocytes reduced by steroid treatment. There is very little GFAP staining in the grey matter in WT mice, either in
the cranial motor nuclei (A, E, I), or spinal cord (M). In the SOD1G93A saline group there was a marked GFAP up-regulation in the trigeminal
(B), facial (F) and hypoglossal (J) nuclei, as well as the ventral spinal cord (N). A similar staining pattern is observed in SOD1G93A mice treated
with free MP (C, G, K, O). GFAP staining in SOD1G93A 2B3-201 mice, however, was significantly reduced in all cranial motor nuclei (D, H, L), but
not in the ventral spinal cord (P). Panels Q, S, U and W show quantification of GFAP staining intensity in the brainstem motor nuclei and spinal
cord, and panels R, T, V and X show the density of GFAP+ astrocytes in these same regions. There is increased expression in all SOD1G93A treatment
groups compared with WT mice, but SOD1G93A mice treated with 2B3-201 have less of a GFAP response compared with those treated with saline
and free MP. Scale bar applies to all images. * p<0.05; ** p<0.01; *** p<0.001.
Evans et al. Acta Neuropathologica Communications 2014, 2:66 Page 8 of 13
http://www.actaneurocomms.org/content/2/1/66groups. However, unlike for the cranial motor nuclei, no
significant differences were found between SOD1G93A
treatment groups with regards to either GFAP staining in-
tensity or number of astrocytes.
Discussion
Overall, we present data showing that glutathione PEGy-
lated liposomal methylprednisolone (2B3-201) reduced
brainstem neuronal loss and degeneration, and attenu-
ated brainstem astrocyte reactivity in the SOD1G93A
mouse model of ALS.
There was no significant difference between SOD1G93A
mice treated with 2B3-201 compared with saline in
regards to our behavioural outcomes (weight and rotarod).
However, Rotarod score does not reflect all of the various
motor neuron populations relevant for ALS (i.e. spinal,
cranial and cortical); rotarod performance requires balance
and motor skills of the fore- and hind-limbs, and, as a
consequence, it will primarily reflect physiology of lumbar
motor neurons (for hind limbs), cervical motor neurons
(for fore limbs) and cerebellar neurons (for balance).
Therefore, a significant improvement in neuronal healthand alterations in the inflammatory environment in the
cranial nuclei would not be reflected in the rotarod score.
As ALS progresses there is substantial involvement of
cranial neuropathy to clinical symptoms, many of which
ultimately contribute to early death of patients. The func-
tion of these motor nuclei is not easy to determine with
standard behavioral testing, for example studies of ability
to eat (a test of trigeminal, facial, glossopharyngeal, vagus
and hypoglossal nerve function) are confounded by affect,
appetite or general mobility, which may be separately al-
tered in neurodegenerative disease. MRI affords an oppor-
tunity to examine the structural integrity of the higher
motor centres.
As has been shown in previous studies from our group
and elsewhere [3-5], SOD1G93A mice had T2 hyperinten-
sity in the brainstem motor nuclei, which was signifi-
cantly attenuated by 2B3-201 treatment, suggesting that
2B3-201, but not free steroid, ameliorates brainstem
pathology. The increased T2 signal intensity has been
shown to correlate with vacuolization associated with
neuronal cell death, as well as astrocyte and microglia
activation [3,4]. To discover whether the positive effects
Evans et al. Acta Neuropathologica Communications 2014, 2:66 Page 9 of 13
http://www.actaneurocomms.org/content/2/1/66of 2B3-201 on T2 MRI signal correlated with increased
neuronal cell survival we examined post-mortem tissue
with histology and immunohistochemistry.
We showed a specific therapeutic effect for 2B3-201
(but not free MP) in reducing not only brainstem vacu-
olation, but also reducing the neuronal loss in these
nuclei, and increasing the number of histologically
“healthy” appearing neurons on histology, thus con-
firming the T2 MRI findings. However, there was no
therapeutic effect, either for free or packaged steroid,
for spinal (ventral horn) neuronal loss. There are no
published reports to date of glucocorticoid treatment
in SOD1 mouse models of ALS, which is surprising given
the interest many groups have in the influence of neuro-
inflammation in the disease. The results presented here
are consistent with reports in the Wobbler mouse, show-
ing that corticosterone and 21-aminosteroids can have
therapeutic effect in models of motor neuron degener-
ation [17,22,23]. However, the pathology in the Wobbler
mouse is more diffuse and is now regarded as less rele-
vant to ALS.
Glucocorticoids tend to up-regulate anti-inflammatory
gene expression [24] and interfere with regulation of
pro-inflammatory genes [25]. To discover whether the
effects of the 2B3-201 administration could be attrib-
uted, at least in part, to the suppression of the CNS in-
flammatory response we examined the morphology of
astrocytes and microglia. Glial cells are know to contrib-
ute to neuronal pathology in both humans, and animal
models of ALS [10,11], so we postulated that 2B3-201
treatment exerted its effects by altering the inflammatory
environment of the CNS, through astrocytes or micro-
glia. In line with previous reports, we found that there
was marked activation of astrocytes and microglia in
both the cranial motor nuclei and ventral horn of the
spinal cord in SOD1G93A mice treated with saline [10,11].
There was no effect of free MP administration on micro-
glial activation at any site, but administration of 2B3-201 to
SOD1G93A mice significantly reduced GFAP immunoreac-
tivity in the cranial nuclei, but not in the ventral horn of
the spinal cord. Given the importance of microglia in the
initiation of neurodegeneration in SOD1 mice, it is surpris-
ing that preservation of neurons was not associated with
obvious changes in microglia reactivity. However, much of
the work done to date in SOD1-ALS (and indeed ALS in
general) in regard to neuron-microglia interactions has
been correlational, and our understanding of the relation-
ship between microglial activation and neuronal degener-
ation in this model is still limited. The dissociation
between microglial activation and neuronal survival, how-
ever, is strong evidence that factors other than microglia
are relevant for neuronal survival in SOD1G93A mice.
The astrocyte-specific anti-inflammatory effect of 2B3-
201 raises the possibility that the positive effects of thedrug may be mediated by improving astrocyte function.
Support for this notion comes from recent work show-
ing astrocyte dysfunction in the SOD1G93A mouse alters
motor neuron function at a gene transcription level [26].
Studies from other neuroinflammatory models, such as
experimental autoimmune encephalomyelitis (EAE), have
indicated that reactive, GFAP-positive astrocytes can have
impaired glutamate metabolism, with decreased action of
glutamate dehydrogenase and glutamine synthetase, which
results in higher glutamate concentration and potential
excitotoxicity [27]. It would be of interest, therefore, to in-
vestigate whether the effect on neuronal survival and re-
duced vacuolation shown here is mediated by metabolic
changes induced by a phenotypic shift of astrocytes.
The superior efficacy of 2B3-101, glutathione PEGy-
lated liposomal methylprednisolone, compared to the
free methylprednisolone highlights the importance of
CNS targeting of therapeutic agents. A number of stud-
ies have shown altered BBB permeability as a part of dis-
ease pathogenesis in SOD1 rodent models [28-30], but
such dysfunction appears to occur at the end of the dis-
ease, if at all, and is unlikely to facilitate drug entry to
the brain. In fact, recent work indicates that the function
of the p-glycoprotein efflux transporter at the BBB is up-
regulated as part of disease progression in the SOD1
mice [31], which would greatly reduce the therapeutic
potential for a non-encapsulated steroid treatment. This
may go some way to explain why free prednisolone was
not effective as a treatment in ALS patients [18].
When interpreting these data, it is important to note
that the assessment of neuronal health in this report is a
purely morphological one. Whilst highly vacuolated cells
are highly likely to have functional deficits, this could be
confirmed with electrophysiological analysis. Also, the
analysis of phenotypic changes in astrocytes and microglia
used here is only based on one, well-validated, marker each
using immunohistochemistry. One important goal for the
future will be to use other markers to delve deeper in the
phenotype of these cell types and their associated func-
tional state.
Overall, the therapeutic effect of 2B3-201 was limited
to the cranial motor areas – substantial motor neuron
loss was evident in all three SOD1G93A groups within the
ventral horn of the spinal cord, and no amelioration was
found with 2B3-201 treatment for either neuronal, tissue
integrity (vacuolation) or inflammatory parameters. This
was surprising, as previous work using glutathione
PEGylated liposomes encapsulating a fluorescent tracer
has found a high delivery to the spinal cord, in addition
to higher cerebral structures [32]. It is unclear from this
work why 2B3-201 did not affect the spinal cord in this
model. However, It is worth noting that while most stud-
ies investigating potential therapeutic compounds for
ALS are focused towards ameliorating the spinal cord
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respiratory muscles, which may have a brainstem compo-
nent [33,34]. Moreover, towards the end of disease (or at
earlier disease points for patients with bulbar-onset ALS),
dysphagia may occur due to bulbar degeneration, poten-
tially causing malnutrition unless the patients undergo
gastrostomy feeding [35]. Malnutrition may have conse-
quences to other body systems, and associated dysphagia
may lead to aspiration pneumonia [36]. Dysphagia has
also been highlighted as a major factor in impairing qual-
ity of life for ALS patients [37]. Therefore, targeting
brainstem pathology in ALS patients has important
therapeutic potential. We chose to employ a treatment
regime beginning at 60 days, and it remains possible that
earlier intervention with the steroid may have had more
of a beneficial effects on the spinal pathology should
it have been given earlier. It remains unclear at what
point cell death becomes irreversible in SOD1G93A mouse
pathology.
Conclusions
This work has shown that a CNS-targeted anti-
inflammatory steroid treatment (glutathione PEGylated
liposomal methylprednisolone) can significantly amelior-
ate pathology in a SOD1G93A mouse model of ALS, redu-
cing signs of neurological damage by as much as 40%. It
also confirms the potential of MRI as a biomarker of dis-
ease progression and drug efficacy in ALS [38]. History
suggests that caution should be exercised in assum-
ing translation of benefit from the SOD1 mouse to
human ALS [39]. Nonetheless, we highlight an important
principle, namely that drugs with little or no effect fol-
lowing standard systemic administration may have sig-
nificant effects on the pathophysiology when targeted to
the CNS through optimized delivery.
Materials and methods
Animals and treatments
Female SOD1G93A mice and wild-type (WT) C57BL/6 lit-
termates were sourced from the in-house breeding col-
ony at the University of Oxford. Male SOD1G93A mice
were used to maintain the breeding colony, and were
not used in experiments. Animals were genotyped at
40 days of age, using a DirectPCR Lysis Reagent (Viagen,
York, UK) following standard manufacturer’s directions
to extract DNA and standard PCR was performed using
primers for human SOD1G93A and IL-6 (positive control),
as described on the Jackson laboratory website (http://
jaxmice.jax.org/strain/002726.html). Animals were then
assigned to one of four groups: (1) WT saline (n = 10);
(2) SOD1G93A saline (n = 8); (3) SOD1G93A free methyl-
prednisolone (MP) (n = 9); and (4) SOD1G93A 2B3-201
(n = 10). 2B3-201, glutathione PEGylated liposomal MP,
was prepared as previously described [21]. Treatmentswere started on day 60 and animals were treated with
either saline (groups 1, 2), 10 mg/kg free MP (group 3)
or 10 mg/kg MP packaged in 2B3-201 (group 4) by
intravenous injection once a week for 9 weeks (until
day 116). All animal procedures were conducted with UK
Home Office approval (licence number 30/2524).
Behavioural testing
Immediately prior to each injection, animal weights were
recorded and behaviour was tested on a rotarod using
an accelerating paradigm, starting at 4 rotations/minute
and accelerating to 40 rotations/minute over 5 minutes.
The time taken for an animal to fall from the apparatus
was recorded in triplicate for each animal, and the lon-
gest time was used in the analysis.
Magnetic resonance imaging (MRI)
For MRI, all animals were anaesthetised using 2.5%
isofluorane (IsoFlo®, Abbot Laboratories, Maidenhead)
for induction, and subsequently maintained with 1-2%
isoflurane in 30% O2 and 70% NO2, a flow rate of
1.5 L/min. MRI data were acquired on a 7T magnet
with a Varian Inova spectrometer (Varian Inc., subsid-
iary of Agilent Technologies, Santa Clara, CA, USA).
T2-weighted images were acquired using a fast spin-
echo multislice (fSEMS), sequence: TR = 3000 ms;
TE = 61.9 ms; FOV = 25 x 25 mm; Matrix size = 128 x 128;
number of slices = 11; averages = 2; slice thickness = 1 mm;
scanning time = 3 mins 12 sec. ROIs were placed over
the three motor nuclei (trigeminal, facial and hypo-
glossal), as well as a control region on the same slices
as the nuclei (within the brainstem, but outside of the
nuclei of interest), and intensities were measured as
(ROI-control)/control.
Tissue preparation
Following MRI, animals were terminally anaesthetized
and perfusion-fixed with PLPlight (75mM lysine HCL,
10 mM di-sodium hydrogen orthophosphate, 10 mM
sodium periodate, 2% PFA, 0.05% gluteraldehyde), and,
after removal of the brain and spinal cord, the tissue was
further fixed by immersion in the same fixative. Tissue
was cryo-protected with 30% sucrose, and then frozen in
OCT (Sigma) and 10-μm-thick sections were cut; each
adjacent section was 150μm apart. Immunohistochemis-
try was performed using a standard protocol for frozen
sections using the following primary antibodies: rabbit
polyclonal GFAP (1:1,000, 24°C, 4 hours) and goat poly-
clonal Iba-1 (1:500, 24°C, 3 hours). All primary anti-
bodies were diluted in PBS with 0.1% Tween, all washes
were with PBS. Secondary antibodies, either biotinyl-
ated horse anti-goat IgG or goat anti-rabbit IgG, were
diluted 1:100, and incubated on the tissue sections for
1 hour at 24°C. Biotin was bound to HRP-Streptavidin
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1 hour at 24°C, and reaction product developed with
DAB (Sigma). Tissue processing was optimised so that
very little GFAP or Iba1 staining in brainstem nuclei
and spinal cords in wild type animals, but good stain-
ing in inflammatory tissue. Tissue was also stained
with haematoxylin and eosin (H&E).
Vacuolation/immunohistochemistry analysis
Vacuolation was assessed in H&E sections. Photographs
were taken of left and right brainstem or spinal cord
hemispheres from 2 sections per brain at 20x magnifica-
tion. For selection of sections for analysis, the largest
two cross sections through the nucleus were selected for
each animal. For assessment of vacuolation, images were
binarised by thresholding using ImageJ, creating a black
mask over the tissue (value 0) and a bright mask over
the vacuoles (value 266). Amount of tissue vacuolation
was then calculated as follows: the area of tissue where
vacuolation was present was measured (mm2), and
within this the binarized mask was averaged on a pixel-
by-pixel basis to obtain a measure of the proportion of
this area affected by vacuolation. By dividing the area
by the proportion affected, the total area of tissue re-
placed by vacuoles was calculated. Vacuolation of WT
mice was measured in the same way as the SOD1G93A
tissue as a baseline control, except that an arbitrary
ROI was used, placed around the boundary of the nu-
cleus, with the size consistent with the ROI for
SOD1G93A. We have previously published using this
method, showing excellent group separation between
SOD1G93A and wild type control throughout much of
the extent of the disease [5].
For quantification of both GFAP and Iba1 immuno-
staining, the two largest cross sections of the brainstem
nuclei in both hemispheres (total 4 regions), or the left
and right ventral horns (total 4 regions) were photo-
graphed at 20x magnification, using Leica Firecam soft-
ware. In ImageJ, the image was deconvolved to split the
brown DAB channel from the blue haematoxylin chan-
nel, and then the average staining intensity was mea-
sured in an ROI of diameter 500 units on ImageJ placed
over the motor nucleus. In addition to the average
staining intensity, the average number of astrocytes
stained with GFAP and microglia stained with Iba1
were counted in the same regions of the brainstem and
spinal cord. All histological analysis, including selection
of sections for analysis, was performed blinded to treat-
ment group.
Neuronal number estimation
The number of neurons was counted in the trigeminal,
facial and hypoglossal nuclei, and a 760 μm segment of
the lumbar spinal cord, using an optical fractionatormethod after West et al. [40]. Brainstem and spinal cord
sections were cut at 10 μm (post-processing thickness
6 μm), adjacent sections were 150 μm apart, and
stained with H&E. Cells were randomly sampled using
a sampling grid of squares 75 μm x 75 μm in dimen-
sion, separated by 150 μm in x and y directions, using
StereoInvestigator software using a x20 objective lens.
Cells were only counted when nuclei appeared within
the thickness of the section. The total number of neu-
rons was counted, and the number of morphologically
normal neurons was also recorded; these quantities
were used to calculate the percentage of healthy neu-
rons. Morphologically normal neurons display a regular
staining pattern with H&E, whereas abnormal neurons
show intracellular vacuolation and often have a with-
ered, pyknotic appearance (see Figure 4).Statistical analysis
For the behavioural data, repeated measure ANOVAs
(within-subjects factor time, between subjects factor
treatment) and Holm-Bonferroni t-tests were carried out
at each time point. Greenhouse-Geisser correction was
used because Mauchly’s test of sphericity was significant
(p<0.001) Area under the curve (AUC) analysis was also
performed using the trapezoid rule, and group means
were compared using a one-way ANOVA followed by
Bonferroni-corrected t tests. MRI and histology data
were not normally distributed, and could not be normal-
ized by transformation; therefore Kruskal-Wallis analysis
was used to investigate differences between treatment
groups in the three brainstem motor nuclei. Individual
comparisons were made using Mann-Whitney U tests
(corrected for multiple comparisons). SPSS (SPSS Inc.,
Chicago, USA) was used for all parametric and non-
parametric statistical analysis. Data are presented as
mean ± standard error for behavioural data and median
[interquartile range] for all other data. Similarly means
and standard errors are graphically represented by bar
graphs with standard error bars, whereas box and whis-
ker plots are used and display the median (strong central
band), interquartile range (box) and range (whiskers) for
all corresponding non-parametric analyses.
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